179 related articles for article (PubMed ID: 30534379)
1. Pharmacological profile of the neuropeptide S receptor: Dynamic mass redistribution studies.
Ruzza C; Ferrari F; Guerrini R; Marzola E; Preti D; Reinscheid RK; Calo G
Pharmacol Res Perspect; 2018 Dec; 6(6):e00445. PubMed ID: 30534379
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo pharmacological characterization of the novel neuropeptide S receptor ligands QA1 and PI1.
Camarda V; Ruzza C; Rizzi A; Trapella C; Guerrini R; Reinscheid RK; Calo G
Peptides; 2013 Oct; 48():27-35. PubMed ID: 23911665
[TBL] [Abstract][Full Text] [Related]
3. Label-free versus conventional cellular assays: Functional investigations on the human histamine H
Lieb S; Littmann T; Plank N; Felixberger J; Tanaka M; Schäfer T; Krief S; Elz S; Friedland K; Bernhardt G; Wegener J; Ozawa T; Buschauer A
Pharmacol Res; 2016 Dec; 114():13-26. PubMed ID: 27751876
[TBL] [Abstract][Full Text] [Related]
4. Neuropeptide S reduces mouse aggressiveness in the resident/intruder test through selective activation of the neuropeptide S receptor.
Ruzza C; Asth L; Guerrini R; Trapella C; Gavioli EC
Neuropharmacology; 2015 Oct; 97():1-6. PubMed ID: 25979487
[TBL] [Abstract][Full Text] [Related]
5. Applying label-free dynamic mass redistribution assay for studying endogenous FPR1 receptor signalling in human neutrophils.
Christensen HB; Gloriam DE; Pedersen DS; Cowland JB; Borregaard N; Bräuner-Osborne H
J Pharmacol Toxicol Methods; 2017 Nov; 88(Pt 1):72-78. PubMed ID: 28716665
[TBL] [Abstract][Full Text] [Related]
6. [tBu-D-Gly5]NPS, a pure and potent antagonist of the neuropeptide S receptor: in vitro and in vivo studies.
Ruzza C; Rizzi A; Camarda V; Pulga A; Marzola G; Filaferro M; Novi C; Ruggieri V; Marzola E; Vitale G; Salvadori S; Guerrini R; Calo' G
Peptides; 2012 Apr; 34(2):404-11. PubMed ID: 22342393
[TBL] [Abstract][Full Text] [Related]
7. Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S and its receptor.
Guerrini R; Salvadori S; Rizzi A; Regoli D; Calo' G
Med Res Rev; 2010 Sep; 30(5):751-77. PubMed ID: 19824051
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of dynamic mass redistribution technology for pharmacological studies of recombinant and endogenously expressed g protein-coupled receptors.
Lee PH; Gao A; van Staden C; Ly J; Salon J; Xu A; Fang Y; Verkleeren R
Assay Drug Dev Technol; 2008 Feb; 6(1):83-94. PubMed ID: 18336088
[TBL] [Abstract][Full Text] [Related]
9. Neuropeptide S receptor ligands: a patent review (2005-2016).
Ruzza C; Calò G; Di Maro S; Pacifico S; Trapella C; Salvadori S; Preti D; Guerrini R
Expert Opin Ther Pat; 2017 Mar; 27(3):347-362. PubMed ID: 27788040
[TBL] [Abstract][Full Text] [Related]
10. Label-free cell phenotypic profiling and pathway deconvolution of neurotensin receptor-1.
Hou T; Shi L; Wang J; Wei L; Qu L; Zhang X; Liang X
Pharmacol Res; 2016 Jun; 108():39-45. PubMed ID: 27117668
[TBL] [Abstract][Full Text] [Related]
11. Structure-Activity Relationship Studies on Oxazolo[3,4-
Albanese V; Ruzza C; Marzola E; Bernardi T; Fabbri M; Fantinati A; Trapella C; Reinscheid RK; Ferrari F; Sturaro C; Calò G; Amendola G; Cosconati S; Pacifico S; Guerrini R; Preti D
J Med Chem; 2021 Apr; 64(7):4089-4108. PubMed ID: 33733768
[TBL] [Abstract][Full Text] [Related]
12. Dynamic mass redistribution as a means to measure and differentiate signaling via opioid and cannabinoid receptors.
Codd EE; Mabus JR; Murray BS; Zhang SP; Flores CM
Assay Drug Dev Technol; 2011 Aug; 9(4):362-72. PubMed ID: 21323580
[TBL] [Abstract][Full Text] [Related]
13. The Physio-Pharmacological Role of the NPS/NPSR System in Psychiatric Disorders: A Translational Overview.
Ghazal P
Curr Protein Pept Sci; 2016; 17(4):380-97. PubMed ID: 26680586
[TBL] [Abstract][Full Text] [Related]
14. NOP receptor pharmacological profile - A dynamic mass redistribution study.
Malfacini D; Simon K; Trapella C; Guerrini R; Zaveri NT; Kostenis E; Calo' G
PLoS One; 2018; 13(8):e0203021. PubMed ID: 30161182
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of human and murine neuropeptide s receptor variants.
Reinscheid RK; Xu YL; Okamura N; Zeng J; Chung S; Pai R; Wang Z; Civelli O
J Pharmacol Exp Ther; 2005 Dec; 315(3):1338-45. PubMed ID: 16144971
[TBL] [Abstract][Full Text] [Related]
16.
Ruzza C; Argentieri M; Ferrari F; Armani E; Trevisani M; Marchini G; Calo' G
Front Pharmacol; 2023; 14():1267414. PubMed ID: 38035009
[TBL] [Abstract][Full Text] [Related]
17. On the selectivity of the Gαq inhibitor UBO-QIC: A comparison with the Gαi inhibitor pertussis toxin.
Gao ZG; Jacobson KA
Biochem Pharmacol; 2016 May; 107():59-66. PubMed ID: 26954502
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo pharmacological characterization of the neuropeptide s receptor antagonist [D-Cys(tBu)5]neuropeptide S.
Camarda V; Rizzi A; Ruzza C; Zucchini S; Marzola G; Marzola E; Guerrini R; Salvadori S; Reinscheid RK; Regoli D; Calò G
J Pharmacol Exp Ther; 2009 Feb; 328(2):549-55. PubMed ID: 18971372
[TBL] [Abstract][Full Text] [Related]
19. Neuropeptide S ameliorates olfactory spatial memory impairment induced by scopolamine and MK801 through activation of cognate receptor-expressing neurons in the subiculum complex.
Shao YF; Wang C; Xie JF; Kong XP; Xin L; Dong CY; Li J; Ren WT; Hou YP
Brain Struct Funct; 2016 Jul; 221(6):3327-36. PubMed ID: 26323488
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
